SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on
the development of oral small-molecule drugs that target immune drivers
of cancer and other immune-related disorders, today announced that Brian
Wong, M.D., Ph.D., CEO will present a corporate update and company
overview at the Cowen and Company 39th Annual Health Care
Conference on Monday, March 11, 2019 at 3:00 p.m. ET in Boston, MA.
A live webcast and audio archive of the presentation may be accessed here
or on the FLX Bio website at https://www.flxbio.com/newsroom.
Please connect to the website 10 minutes prior to the presentation to
ensure adequate time for any software downloads that may be necessary to
listen to the webcast.
About FLX Bio
FLX Bio, Inc. is a privately-held biopharmaceutical company focused on
the discovery, development and commercialization of best-in-class, oral
small molecule therapeutics for the treatment of cancers and other
immune disorders. Our lead compounds inhibit the CCR4 pathway which
plays a key role in both suppressing the immune response to cancer and
in the initiation, progression and persistence of allergic inflammation.
We leverage big data and machine learning together with our advanced
drug discovery capabilities and deep biology expertise, to develop
therapeutics that address key pressure points in pathways that propagate
an abnormal immune response.
Located in South San Francisco, Calif., and funded by leading investors,
including The Column Group (TCG), Kleiner Perkins (KP), Topspin
Partners, GV (formerly Google Ventures) and Celgene Corporation, FLX Bio
has assembled a leadership team and advisory group with a proven track
record of success and team of scientists with substantial knowledge and
expertise in drug discovery and translational areas essential to execute
on this approach. For more information, please visit www.flxbio.com.
For FLX Bio, Inc.